Larvicidal activity of Hypoestes forskaolii (Vahl) R. Br root extracts against Anopheles gambiae Giless.s, Aedes aegypti L, and Culex quinquefasciatus Say
Authors Sillo AJ, Makirita WE, Swai H, Chacha M
Received 17 September 2018
Accepted for publication 5 February 2019
Published 26 April 2019 Volume 2019:11 Pages 23—27
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Bal Lokeshwar
Albert J Sillo, Winisia E Makirita, Hulda Swai, Musa Chacha
School of Life Sciences and Bio-Engineering, Nelson Mandela African Institution of Science and Technology, Arusha, Tanzania
Aim: This study aimed to evaluate larvicidal activity of Hypoestes forskaolii R. Br root extract against 3rd instar Anopheles gambiae, Aedes aegypti, and Culex quinquefasciatus.
Methods: A protocol developed by the World Health Organization was adopted, with minor modification using chloroform and methanol extracts with concentrations ranging from 25–750 μg/mL.
Results: The H. forskaolii chloroform extract exhibited very high larvicidal activity after 72 hours of exposure, with LC50 2.0322, 3.8989, 6.0004 μg/mL against A. gambiae, A. aegypti, and C. quinquefasciatus, respectively.
Conclusion: The larvicidal activity of H. forskaolii is reported for the first time in this paper. The effectiveness of H. forskaolii chloroform extract warrants further research to develop botanical mosquito repellants from this source.
Keywords: Hypoestes forskaolii, LC50, Anopheles gambiae, Aedes aegypti, Culex quinquefasciatus
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]